Is BAX a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Margin and operational turnaround, with revenue (ttm, continuing ops) at ~$10.7B. The bear case rests on the Novum LVP pump shipment hold was expected to persist through the year with no committed resolution timeline, pressuring both revenue and profit. Analysts covering it are spread from $17.00 to $40.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The Novum LVP pump shipment hold was expected to persist through the year with no committed resolution timeline, pressuring both revenue and profit. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $17.00, -31.3% from the $24.73 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Margin and operational turnaround. New CEO Andrew Hider brings a lean-manufacturing and continuous-improvement playbook aimed at reversing the sharp operating-margin compression seen recently. The most optimistic analyst target on BAX is $40.00, +61.7% from the $24.73 price. That figure is only reachable if this thesis works close to its best case.

The Novum LVP pump shipment hold was expected to persist through the year with no committed resolution timeline, pressuring both revenue and profit. Elevated debt (around $8.6 billion long-term) constrains flexibility and makes the company sensitive to interest costs. Margins have been hit by special charges, injectable supply constraints, inflation, recall- and hurricane-related items, and tariff exposure. Competition from Becton Dickinson, ICU Medical, B. Braun, and Fresenius Kabi is intense across infusion and IV products. The turnaround is early and could take longer than management projects. The most pessimistic published target is $17.00, -31.3% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Baxter International makes essential hospital and critical-care products, including IV solutions, infusion pumps (the Novum IQ and legacy platforms), premixed and injectable drugs,

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Margin and operational turnaround) stalling in the reported numbers rather than in the narrative, the risk above (the Novum LVP pump shipment hold was expected to persist through the year with no committed resolution timeline, pressuring both revenue and profit) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Baxter makes essential hospital and critical-care products: IV solutions, infusion pumps, premixed and injectable drugs, surgical sealants, and connected-care hardware from its Hillrom business. Its customers are hospitals and health systems worldwide.

Baxter separated its Kidney Care segment, rebranded Vantive, and sold it to the Carlyle Group for roughly $3.8 billion. Vantive is now a standalone vital-organ-therapy company, and Baxter used proceeds to reduce debt and focus on hospital products.

On an adjusted basis Baxter remains profitable (Q1 2026 adjusted EPS was about $0.36), but GAAP results have swung to small losses on special charges. Adjusted operating margin compressed recently due to a pump shipment hold, supply constraints, and inflation.